8 news items
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
).8 Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of the gastrointestinal tract
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK
27 Mar 24
IBD is a lifelong condition characterized by chronic inflammation in the gastrointestinal
Takeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japan For Patients With Congenital Thrombotic Thrombocytopenic Purpura
TAK
26 Mar 24
cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic
Takeda Announces U.S. FDA Approval Of Supplemental New Drug Application For ICLUSIG In Adult Patients With Newly Diagnosed Ph+ ALL
TAK
19 Mar 24
are indicated or T315I-positive Ph+ ALL, chronic-phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors, accelerated phase (AP
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
TAK
13 Mar 24
evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP
o8llkvxrlqdnjh0gg0q03dk249qpw1gaqngv6klnbr
TAK
13 Feb 24
colitis – causes chronic inflammation of the gastrointestinal (GI) tract which impacts food digestion, nutrition absorption and waste elimination
zqou6kwtcq2tc5s5ygkb2hopp7pgtfyz4rhw0iyvpqc4t4ronpc6yqzi74r
TAK
12 Feb 24
with eosinophilic esophagitis (EoE), a chronic, immune-mediated, inflammatory disease localized in the esophagus, a tube through which the food reaches
vq40b22j3 u7sui9qgtoizhp59xhaaqmzdm30rolb6ft74n0fom9n1gz6i
TAK
12 Feb 24
and Older— EoE Is a Chronic Disease That Can Significantly Impact Patients, with Esophageal Inflammation
- Prev
- 1
- Next